問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Cancer Center

Division of Hematology & Oncology

更新時間:2023-09-19

李日翔Lee, Jih-Hsiang
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

篩選

List

422Cases

2023-03-01 - 2029-04-01

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2021-10-01 - 2025-12-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-08-30 - 2028-03-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2022-04-05 - 2024-07-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-04-30 - 2026-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-11-29 - 2029-03-02

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-03-31 - 2028-01-31

Phase I

Active
A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors
  • Condition/Disease

    Metastatic Solid Tumor、 Advanced Solid Tumor

  • Test Drug

    靜脈點滴注射劑 靜脈點滴注射劑

Participate Sites
10Sites

Recruiting10Sites

2024-06-01 - 2030-12-31

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2021-03-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2024-02-26 - 2037-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites